GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adhera Therapeutics Inc (OTCPK:ATRX) » Definitions » ROA %

Adhera Therapeutics (Adhera Therapeutics) ROA % : -22,450.79% (As of Sep. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Adhera Therapeutics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Adhera Therapeutics's annualized Net Income for the quarter that ended in Sep. 2023 was $-14.14 Mil. Adhera Therapeutics's average Total Assets over the quarter that ended in Sep. 2023 was $0.06 Mil. Therefore, Adhera Therapeutics's annualized ROA % for the quarter that ended in Sep. 2023 was -22,450.79%.

The historical rank and industry rank for Adhera Therapeutics's ROA % or its related term are showing as below:

ATRX' s ROA % Range Over the Past 10 Years
Min: -6447.72   Med: -198.22   Max: 39.7
Current: -3969.91

During the past 13 years, Adhera Therapeutics's highest ROA % was 39.70%. The lowest was -6447.72%. And the median was -198.22%.

ATRX's ROA % is ranked worse than
99.61% of 1554 companies
in the Biotechnology industry
Industry Median: -35.515 vs ATRX: -3969.91

Adhera Therapeutics ROA % Historical Data

The historical data trend for Adhera Therapeutics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adhera Therapeutics ROA % Chart

Adhera Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -295.89 -430.79 -1,789.07 -6,447.72 -1,537.45

Adhera Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,170.78 -800.00 -3,873.22 1,165.59 -22,450.79

Competitive Comparison of Adhera Therapeutics's ROA %

For the Biotechnology subindustry, Adhera Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adhera Therapeutics's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adhera Therapeutics's ROA % distribution charts can be found below:

* The bar in red indicates where Adhera Therapeutics's ROA % falls into.



Adhera Therapeutics ROA % Calculation

Adhera Therapeutics's annualized ROA % for the fiscal year that ended in Dec. 2022 is calculated as:

ROA %=Net Income (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=-2.114/( (0.196+0.079)/ 2 )
=-2.114/0.1375
=-1,537.45 %

Adhera Therapeutics's annualized ROA % for the quarter that ended in Sep. 2023 is calculated as:

ROA %=Net Income (Q: Sep. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=-14.144/( (0.082+0.044)/ 2 )
=-14.144/0.063
=-22,450.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2023) net income data. ROA % is displayed in the 30-year financial page.


Adhera Therapeutics  (OTCPK:ATRX) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2023 )
=Net Income/Total Assets
=-14.144/0.063
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-14.144 / 0)*(0 / 0.063)
=Net Margin %*Asset Turnover
=N/A %*0
=-22,450.79 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Adhera Therapeutics ROA % Related Terms

Thank you for viewing the detailed overview of Adhera Therapeutics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Adhera Therapeutics (Adhera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8000 Innovation Parkway, Baton Rouge, LA, USA, 70820
Adhera Therapeutics Inc is an emerging specialty biotech company that is strategically evaluating its focus including a return to a drug discovery and development company.
Executives
Zahed Subhan director 8000 INNOVATION PARKWAY, BATON ROUGE LA 70820
Trond Kydd Waerness director 8000 INNOVATION PARKWAY, BAON ROUGE LA 70820
Rice Charles L Jr director C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk director, officer: Chief Executive Officer 549 MILGATE PLACE, BATON ROUGE LA 70810
Rhonda L. Stanley officer: SVP Finance & Accounting 5001 SOUTH MIAMA BOULEVARD, SUITE 300, DURHAM NC 27703
Nancy R. Phelan director 812 MAPLEWOOD ROAD, WAYNE PA 19087
Robert Eric Teague officer: Chief Financial Officer C/O MARINA BIOTECH, INC., 4721 EMPEROR BOULEVARD, SUITE 350, DURHAM NC 27703
Uli Hacksell director 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Robert Jr. Moscato officer: CEO 400 PRATT STREET, SUITE 606, BALTIMORE MD 21202
Timothy Boris director 805 AEROVISTA PLACE, SUITE 205, SAN LUIS OBISPO CA 93401
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Peter D. Weinstein officer: Chief Legal Officer C.O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Amit B. Shah officer: Chief Financial Officer 10 AGUILA, ALISO VIEJO CA 92656
Erik C. Emerson officer: Chief Commercial Officer 2300 WEST SAHARA AVENUE, SUITE 800 - #4012, LAS VEGAS NV 89102
Mihir Munsif officer: Chief Operating Officer 21102 BRIARWOOD LANE, TRABUCO CANYON CA 92679